Imugene Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IUGNF research report →
Companywww.imugene.com
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer.
- CEO
- Leslie Chong
- IPO
- 2019
- Employees
- 5
- HQ
- Sydney, NSW, AU
Price Chart
Valuation
- Market Cap
- $44.54M
- P/E
- -0.49
- P/S
- 12.98
- P/B
- 0.68
- EV/EBITDA
- -0.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -65.91%
- Op Margin
- -1960.77%
- Net Margin
- -1864.12%
- ROE
- -134.65%
- ROIC
- -108.88%
Growth & Income
- Revenue
- $4.40M · -11.53%
- Net Income
- $-69,021,612 · 53.89%
- EPS
- $-0.32 · 55.56%
- Op Income
- $-70,940,449
- FCF YoY
- 17.25%
Performance & Tape
- 52W High
- $0.65
- 52W Low
- $0.06
- 50D MA
- $0.11
- 200D MA
- $0.19
- Beta
- 2.36
- Avg Volume
- 18.30K
Get TickerSpark's AI analysis on IUGNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IUGNF Coverage
We haven't published any research on IUGNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IUGNF Report →